Sanofi Sponsored ADR Stock News

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing,...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusion Studies used Enable Injections' enFuse® on-body injector, an automated hands-free i...

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY).

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi

Sanofi SA (ADR) (NYSE:SNY) is placing a major bet on rare immune disorders with its $9.1bn acquisition of US biotech firm Blueprint Medicines, part of a wider push to become a global leader in immunology. The deal gives Sanofi access to Blueprint's lead drug Ayvakit, the only approved treatment for systemic mastocytosis, a rare and often debilitating disease caused by the uncontrolled growth an...

French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday.

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.